{
    "Trade/Device Name(s)": [
        "Calprest\u00aeNG"
    ],
    "Submitter Information": "Eurospital S.p.A.",
    "510(k) Number": "K160447",
    "Predicate Device Reference 510(k) Number(s)": [
        "K130945"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NXO"
    ],
    "Summary Letter Date": "September 29, 2016",
    "Summary Letter Received Date": "October 3, 2016",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21CFR866.5180"
    ],
    "Regulation Name(s)": [
        "Fecal Calprotectin Immunological Test System"
    ],
    "Analyte Class(es)": [
        "immunology"
    ],
    "Analyte(s)": [
        "Calprotectin"
    ],
    "Specimen Type(s)": [
        "Stool"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "96 well microtiter plate"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme-linked immunosorbent assay (ELISA)",
        "Colorimetric detection"
    ],
    "Methodologies": [
        "ELISA"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for Calprest\u00aeNG quantitative ELISA kit for detection of fecal calprotectin to aid in diagnosis of IBD and differentiate from IBS.",
    "Indications for Use Summary": "Quantitative ELISA for detecting concentration of fecal calprotectin to aid in diagnosis of Inflammatory Bowel Diseases (IBD), specifically Crohn\u2019s disease and ulcerative colitis, and to differentiate IBD from Irritable Bowel Syndrome (IBS) in conjunction with other clinical and laboratory findings.",
    "fda_folder": "Immunology"
}